Form 4: Immunovant CEO Peter Salzmann Receives Stock Options and Restricted Stock Units

Peter Salzmann, CEO of Immunovant, Inc., was granted stock options and restricted stock units (RSUs) on April 1, 2025, according to a Form 4 filing.

Summary

• Peter Salzmann, the CEO of Immunovant, Inc., received 265,820 restricted stock units (RSUs) and options to purchase 374,395 shares of common stock on April 1, 2025.
• The RSUs were granted under the company's 2019 Equity Incentive Plan, with each RSU representing the right to receive one share of common stock upon vesting.
• 25% of the RSUs will vest on April 1, 2026, and the remaining units will vest in equal quarterly installments over the following three years, contingent upon Salzmann's continued service.
• The stock options have an exercise price of $15.20 and also vest with 25% of the shares vesting on April 1, 2026, and the remainder vesting in 36 equal monthly installments over three years, subject to continued service.
• Following these transactions, Salzmann directly owns 1,214,606 shares of Immunovant common stock and 374,395 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity to the CEO is a standard practice and generally viewed as a positive sign of alignment with shareholder interests. However, it's not a major catalyst for significant price movement.

Positives

• The grant of RSUs and stock options aligns the CEO's interests with those of the shareholders, incentivizing him to drive long-term value creation.
• The vesting schedule encourages continued service and commitment from the CEO.

Industry Context

Grants of stock options and restricted stock units are a common practice in the biotechnology industry to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are common in the biotech industry.
• Companies like Amgen, Regeneron, and Biogen also utilize equity-based compensation to align executive incentives with shareholder value.
• The vesting schedules and grant sizes are generally comparable to industry norms for companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of alignment between management and shareholder interests.
• Employees may see the equity grants as a sign of the company's commitment to its leadership.

Key Dates

Keywords

Immunovant, Peter Salzmann, CEO, Form 4, Stock Options, Restricted Stock Units, RSUs, Equity Incentive Plan, Vesting